Publications by authors named "Sait Kitapli"
Article Synopsis
- The study examines the role of Her2 status in early stage triple negative breast cancer (TNBC) patients undergoing neoadjuvant chemotherapy, revealing conflicting results regarding its prognostic impact.
- A total of 620 female TNBC patients were analyzed, with 68.9% having Her2-0 and 31.1% having Her2-low status; the rates of pathological complete response (pCR) were similar between these groups.
- While the Her2-0 group showed better disease-free survival (DFS), the overall survival (OS) rates were similar between the two groups, indicating the need for further research into the implications of Her2 status in this treatment context.
The COVID-19 pandemic caused by the SARS-CoV-2 virus has been studied predominantly in terms of its immediate respiratory and systemic effects. However, emerging evidence suggests possible long-term effects, including its role in carcinogenesis. This comprehensive review explores the complex relationship between COVID-19 and cancer development, focusing on immune dysregulation, chronic inflammation, genetic and epigenetic alterations, and the impact of therapeutic interventions.
View Article and Find Full Text PDFWhile some clinics have adopted abbreviated neoadjuvant treatment for HER2-positive breast cancer, there remains a shortage of comprehensive clinical data to support this practice. This is a retrospective, multicenter study. A total of 142 patients were included in the study who are HER2-positive breast cancer, aged ≤ 65 years, with left ventricular ejection fraction ≥ 50%, received neoadjuvant chemotherapy and underwent surgery at 10 different oncology centers in Türkiye between October 2016 and December 2022.
View Article and Find Full Text PDF